Free NHS GMS SCN1A testing confirms 75% of clinical Dravet syndrome diagnoses in the UK, feeding a NICE-sequenced treatment algorithm (cannabidiol first, then fenfluramine) delivered across 25 dedicated NHS paediatric epilepsy centres.
Dravet syndrome is a severe, genetically defined developmental and epileptic encephalopathy, with de novo SCN1A pathogenic variants confirmed in an estimated 80–90% of UK cases (no family history) and clinical molecular confirmation running at roughly 75%. An estimated 400–500 patients are living with Dravet syndrome in the UK. The NHS Genomic Medicine Service offers SCN1A testing free of charge as part of an epilepsy gene panel to any patient presenting with febrile-seizure-onset epilepsy, with standard turnaround of 8–16 weeks and a fast-track route of under 2 weeks for infantile encephalopathy presentations — placing the UK among the highest molecular-confirmation-rate countries for Dravet syndrome globally.
Management runs on a NICE-defined sequence rather than physician discretion: valproate and clobazam first, with sodium-channel blockers contraindicated and documented, then cannabidiol (Epidiolex, NICE TA614, 2019) added and reassessed at 12 weeks, then fenfluramine (Fintepla, NICE TA887, 2022) added for inadequate responders. Both agents require prescription through one of 25 NHS Highly Specialised Service paediatric epilepsy centres, and fenfluramine carries a mandatory cardiac monitoring obligation — the Fintepla Cardiac Monitoring Scheme (FCMS). SUDEP risk (2–18% lifetime, depending on seizure control) is a structural feature of NHS Dravet management: NICE NG217 (2022) mandates a SUDEP risk discussion at every epilepsy review, and the NHS 'SUDEP and Seizure Safety Checklist' is used at all UK epilepsy centres.
NICE-recommended Dravet syndrome therapies — United Kingdom, 2026
| Drug (Brand / INN) | Class | Company | NICE Status | Sequence Position | Monitoring Requirement |
|---|---|---|---|---|---|
| Epidiolex (cannabidiol) | Oral CBD | Jazz Pharmaceuticals | NICE TA614 — recommended (2019) | Added to valproate + clobazam; reassessed at 12 weeks | Standard epilepsy follow-up |
| Fintepla (fenfluramine) | Serotonin-releasing agent | UCB | NICE TA887 — recommended (2022) | Second-line after inadequate CBD response | Mandatory cardiac monitoring (FCMS) |
Sources: NICE TA614 (2019) and TA887 (2022) commissioning documents; NHS England Highly Specialised Service specification; NHS GMS epilepsy gene panel specifications; Dravet UK Society data 2023.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- SCN1A gene panel access and turnaround
- molecular confirmation rate vs clinical diagnosis
- de novo mutation prevalence
- fast-track pathway for infantile encephalopathy presentations
Delivers
- NICE-defined treatment algorithm and reassessment points
- cardiac monitoring obligation for fenfluramine
- the evidence bar a new agent must clear over CBD+fenfluramine background
Delivers
- SUDEP risk range and NICE NG217 monitoring mandate
- the NHS Seizure Safety Checklist
- Genomics England 100,000 Genomes Project Dravet cohort as a long-term outcomes resource
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How de novo SCN1A pathogenic variants, confirmed in 80-90% of UK cases with no family history, define Dravet syndrome as a genetically determined encephalopathy
- Why clinical molecular confirmation of SCN1A runs at roughly 75% despite the high de novo mutation rate seen in UK Dravet cases
- How the NHS Genomic Medicine Service's free SCN1A epilepsy gene panel, with 8-16 week standard turnaround, places the UK among the highest confirmation-rate countries globally
- The under-2-week fast-track SCN1A testing route for infantile encephalopathy presentations against an estimated 400-500 UK Dravet patients
- The NICE-defined sequence: valproate and clobazam first, cannabidiol (Epidiolex, TA614) added and reassessed at 12 weeks, then fenfluramine (Fintepla, TA887) for inadequate responders
- Why sodium-channel blockers are contraindicated and documented before any NICE-recommended Dravet agent is prescribed
- Why both cannabidiol and fenfluramine require prescription through one of only 25 NHS Highly Specialised Service paediatric epilepsy centres
- How the Fintepla Cardiac Monitoring Scheme (FCMS) mandatory cardiac monitoring obligation is administered across this 25-centre network
- Why lifetime SUDEP risk in Dravet syndrome ranges from 2% to 18% depending on seizure control, and how NICE NG217 mandates a risk discussion at every review
- How the NHS 'SUDEP and Seizure Safety Checklist,' used at all UK epilepsy centres, operationalises NG217's monitoring requirement
- The evidence bar a new Dravet therapy must clear against the NICE-established cannabidiol-plus-fenfluramine background regimen
- How the Genomics England 100,000 Genomes Project Dravet cohort offers a long-term outcomes resource for evaluating pipeline agents
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
UK Dravet syndrome disease landscape is built from primary NHS and NICE sources: NHS Genomic Medicine Service gene panel specifications, NICE technology appraisal documentation, and NHS England Highly Specialised Service commissioning specifications, together with UK patient-organisation and national research-cohort data, not secondary summaries or unverified estimates.
Key sources: NICE TA614 (2019) and TA887 (2022) commissioning documents; NHS England HSS specification; NHS GMS epilepsy gene panel specifications; NICE NG217 epilepsy guideline (2022); Dravet UK Society data 2023; Genomics England 100,000 Genomes Project Dravet cohort; SUDEP Action UK data.
- UK Dravet population estimate verified against Dravet UK Society data 2023
- NICE treatment algorithm verified against NICE TA614 (2019) and TA887 (2022) commissioning documents
- SCN1A gene panel access and turnaround verified against NHS GMS epilepsy gene panel specifications
- SUDEP risk and monitoring mandate verified against NICE NG217 epilepsy guideline 2022 and SUDEP Action UK data
Frequently asked questions
Commission this assessment
AXLRx UK Dravet Syndrome Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the UK Dravet syndrome patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.